A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Pemetrexed (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Aug 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
- 21 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.